Richard A. Gonzalez
Net Worth

Last updated:

What is Richard A. Gonzalez net worth?

The estimated net worth of Mr. Richard A. Gonzalez is at least $415,429,794 as of 5 Aug 2024. He owns shares worth $92,310,227 as insider, has earned $242,159,567 from insider trading and has received compensation worth at least $80,960,000 in AbbVie Inc..

What is the salary of Richard A. Gonzalez?

Mr. Richard A. Gonzalez salary is $7,360,000 per year as Chairman & Chief Executive Officer in AbbVie Inc..

How old is Richard A. Gonzalez?

Mr. Richard A. Gonzalez is 71 years old, born in 1954.

What stocks does Richard A. Gonzalez currently own?

As insider, Mr. Richard A. Gonzalez owns shares in one company:

Company Title Shares Price per share Total value
AbbVie Inc. (ABBV) Chairman & Chief Executive Officer 446,599 $206.7 $92,310,227

What does AbbVie Inc. do?

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV logo
ABBV
AbbVie Inc.
$206.7

Richard A. Gonzalez insider trading

AbbVie Inc.

Mr. Richard A. Gonzalez has made 24 insider trades between 2014-2024, according to the Form 4 filled with the SEC. Most recently he sold 66,500 units of ABBV stock worth $12,403,580 on 5 Aug 2024.

The largest trade he's ever made was exercising 285,953 units of ABBV stock on 2 Jun 2016. As of 5 Aug 2024 he still owns at least 446,599 units of ABBV stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock, $0.01 par value 66,500 $186.52 $12,403,580
Option
Common Stock, $0.01 par value 87,050 $61.36 $5,341,388
Option
Common Stock, $0.01 par value 119,418 $79.02 $9,436,410
Option
Option (Right To Buy) 87,050 $61.36 $5,341,388
Sale
Common Stock, $0.01 par value 282,845 $175 $49,497,875
Option
Common Stock, $0.01 par value 76,377 $93.5 $7,141,250
Option
Option (Right To Buy) 119,418 $79.02 $9,436,410
Option
Option (Right To Buy) 76,377 $93.5 $7,141,250
Sale
Common Stock, $0.01 par value 138,616 $177.27 $24,572,458
Sale
Common Stock, $0.01 par value 60,000 $148.58 $8,914,800
Sale
Common Stock, $0.01 par value 18,500 $149.15 $2,759,275
Option
Common Stock, $0.01 par value 174,100 $61.36 $10,682,776
Sale
Common Stock, $0.01 par value 174,100 $123.14 $21,438,500
Option
Option (Right To Buy) 174,100 $61.36 $10,682,776
Option
Option (Right To Buy) 170,113 N/A N/A
Option
Common Stock, $0.01 par value 170,113 N/A N/A
Sale
Common Stock, $0.01 par value 170,113 N/A N/A
Sale
Common Stock, $0.01 par value 170,113 $108.97 $18,536,703
Option
Common Stock, $0.01 par value 194,154 $56.87 $11,041,538
Option
Option(Right to buy) 194,154 $56.87 $11,041,538
Sale
Common Stock, $0.01 par value 194,154 $97.28 $18,886,330
Sale
Common Stock, $0.01 par value 37,450 $95.74 $3,585,463
Sale
Common Stock, $0.01 par value 16,850 $88.75 $1,495,438
Sale
Common stock, $0.01 par value 8,280 $117.89 $976,088
Option
Common stock, $0.01 par value 218,193 $58.88 $12,847,204
Option
Option (right to buy) 218,193 $58.88 $12,847,204
Sale
Common stock, $0.01 par value 218,193 $58.88 $12,847,204
Option
Common stock, $0.01 par value 193,131 $51.42 $9,930,796
Sale
Common stock, $0.01 par value 193,131 $71.03 $13,718,674
Option
Option (right to buy) 193,131 $51.42 $9,930,796
Sale
Common stock, $0.01 par value 22,038 $71.08 $1,566,439
Option
Option (right to buy) 22,038 $51.42 $1,133,194
Option
Common stock, $0.01 par value 22,038 $51.42 $1,133,194
Option
Option (right to buy) 65,861 $51.42 $3,386,573
Sale
Common stock, $0.01 par value 65,861 $71 $4,676,329
Option
Common stock, $0.01 par value 65,861 $51.42 $3,386,573
Sale
Common stock, $0.01 par value 71,235 $65.49 $4,664,824
Option
Option (right to buy) 18,366 $24.21 $444,604
Sale
Common stock, $0.01 par value 72,016 $64.25 $4,627,028
Option
Common stock, $0.01 par value 72,016 $26.72 $1,924,051
Sale
Common stock, $0.01 par value 285,953 $63.87 $18,263,246
Option
Option(right to buy) 285,953 $35.88 $10,259,994
Sale
Common stock, $0.01 par value 39,000 $63.8 $2,488,200
Option
Option (right to buy) 65,000 $35.88 $2,332,200
Sale
Common stock, $0.01 par value 65,000 $71.19 $4,627,545
Option
Common stock, $0.01 par value 65,000 $35.88 $2,332,200
Sale
Common stock, $0.01 par value 167,183 $64.78 $10,830,449
Option
Common stock, $0.01 par value 175,477 $35.88 $6,296,115
Option
Option (right to buy) 175,477 $35.88 $6,296,115
Sale
Common stock, $0.01 par value 8,294 $64.8 $537,410
Sale
Common stock, $0.01 par value 4,799 $51.2 $245,709

AbbVie key executives

AbbVie Inc. executives and other stock owners filed with the SEC: